US FDA’s Remote Assessments Pose Risks For Drug Manufacturers

 
• By Sue Sutter
  
Sword
FDA remote evaluation tools may be viewed as a double-edged sword, allowing preapproval compliance assessments to keep flowing during COVID but also posing risks to sponsors. • Source: Shutterstock

More from Compliance

More from Pink Sheet